Korro Bio (KRRO) Receivables (2018 - 2025)
Korro Bio (KRRO) posted Receivables of $969000.0 for Q4 2025, up 18.17% on a QoQ basis from $820000.0 in Q3 2025, and down 42.87% year-over-year from $1.7 million in Q4 2024.
Korro Bio (KRRO) Receivables (2018 - 2025) Analysis & Trends
Korro Bio's Receivables history runs 5 years deep, the most recent figure standing at $969000.0 for Q4 2025.
- Quarterly Receivables fell 42.87% year-over-year to $969000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $969000.0 (down 42.87% YoY) and the FY2025 annual result came in at $1.0 million, down 41.18% from the prior year.
- Receivables was $969000.0 for Q4 2025 at Korro Bio, up from $820000.0 in the prior quarter.
- Across five years, Receivables topped out at $10.0 million in Q3 2024 and bottomed at $820000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | - |
| 2 | Nanobiotix | 1,913.26 Bn | 1,913.20 Bn | - | 4.97 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.02 Bn | 466.23 Bn | 1.35 Bn | 938.02 Mn |
| 5 | Vertex Pharmaceuticals | 122.17 Bn | 114.92 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.10 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.60 Bn | 50.42 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Alnylam Pharmaceuticals | 37.39 Bn | 34.38 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Korro Bio | 124.45 Mn | 10.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 969,000.00 |
| Sep 30, 2025 | 820,000.00 |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Dec 31, 2024 | 1.70 Mn |
| Sep 30, 2024 | 10.00 Mn |
| Mar 31, 2020 | 246,000.00 |
| Dec 31, 2019 | 805,000.00 |
| Sep 30, 2019 | 408,000.00 |
| Dec 31, 2018 | 161,000.00 |